Greenstone Announces Voluntary Nationwide Recall Of Citalopram And Finasteride Due To Possible Mislabeling
Main Category: DepressionAlso Included In: Urology / Nephrology; Pharmacy / Pharmacist; Public Health
Article Date: 28 Mar 2011 - 3:00 PDT
'Greenstone Announces Voluntary Nationwide Recall Of Citalopram And Finasteride Due To Possible Mislabeling'
| Patient / Public: | ![]() |
|
| Healthcare Prof: | ![]() |
Greenstone LLC announced today that it is voluntarily conducting a recall, to the patient level, of medicines with lot number FI0510058-A on the label. This includes Citalopram 10mg Tablets (100-count bottle) and Finasteride 5mg Tablets (90-count bottle), both distributed in the U.S. market. The recall is due to the possibility that incorrect labels have been placed on the bottles by a third-party manufacturer. This is the only lot number being recalled and no other lots or markets are believed to be impacted.
Importantly, bottles labeled as Citalopram Lot # FI0510058-A may contain Finasteride. Patients who believe they may have ingested the wrong medication should contact their physician as soon as possible. Women who are, or may become pregnant, should not take or handle Finasteride due to the possible risk of side effects which may cause abnormalities to the external genitalia of a developing male fetus. Citalopram is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or pimozide, It is also contraindicated in patients with a hypersensitivity to Citalopram or any of the inactive ingredients in the tablet. Patients who discontinue Citalopram abruptly by inadvertently taking the mislabeled product may experience discontinuation symptoms and/or worsening of depression.
Bottles of either Citalopram (used to treat depression) or Finasteride (for the treatment of benign prostatic hyperplasia) with lot number FI050058-A should be returned to the pharmacist.
Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product. Also, any adverse events that may be related to the use of these products should be reported to Pfizer Inc. at-1-800-438-1985(24 hours a day) or to FDA's Med Watch Program either online, by regular mail or by fax.
- Online here.
- Regular Mail: Use postage-paid, pre-addressed Form FDA 3500 available here. Mail to the address on the pre-addressed form.
- Fax: 1-800-FDA-0178
Greenstone LLC is a wholly owned subsidiary of Pfizer Inc.
Source:
Pfizer Inc.
Visit our depression section for the latest news on this subject.
MLA
26 May. 2012. <http://www.medicalnewstoday.com/releases/220383.php>
APA
http://www.medicalnewstoday.com/releases/220383.php.
Please note: If no author information is provided, the source is cited instead.
Add Your Opinion On This Article
'Greenstone Announces Voluntary Nationwide Recall Of Citalopram And Finasteride Due To Possible Mislabeling'Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.






